I
InVivo Therapeutics
InVivo Therapeutics (NASDAQ:NVIV) is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.
About InVivo Therapeutics
InVivo Therapeutics is a pioneering company focused on developing innovative treatments for spinal cord injuries (SCI). Operating in the biotechnology sector, InVivo targets a critical unmet medical need by advancing clinical research and development to improve the lives of SCI patients. The company primarily serves patients with acute spinal cord injuries, collaborating with healthcare providers and research institutions to bring cutting-edge therapies to market. InVivo's business model revolves around the development and commercialization of its proprietary technologies, including the Neuro-Spinal Scaffold, which is designed to promote structural support and healing in the spinal cord. Revenue is generated through a combination of product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies. The company is committed to rigorous clinical trials to validate the efficacy and safety of its treatments, ensuring regulatory compliance and striving for market approval. InVivo's market is global, with a focus on regions with high incidences of spinal cord injuries and robust healthcare infrastructures. Key stakeholders include patients, healthcare providers, research institutions, and investors who are aligned with the company's mission to redefine the life of spinal cord injury patients.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2010
News
Open roles
InVivo Therapeutics in the Cambridge ecosystem
The InVivo Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Spencer trask & co
Lincoln Park Capital Fund
SternAegis Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about InVivo Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See InVivo Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

